Johnson & Johnson Adds Eprex Anemia Drug to Recall List
Johnson & Johnson is conducting yet another recall, this time of its Eprex anemia drug, due to a lack of potency, according to recent news sources. The recall affects about 200,000 syringes of the Eprex anemia drug. The drug is sold at the wholesale and pharmacy level. Johnson & Johnson believes most of the product… read more
J&J Hires Outside Counsel for DePuy ASR Hip Replacement Recall
According to recent news reports, Johnson & Johnson is hiring an outside firm to handle the recall of its DePuy ASR metal-on-metal hip implant. This is an unusual move, as companies typically handle these matters with their in-house counsel and rely on the patient’s doctor to determine if a replacement is necessary. However, this decision… read more
Johnson & Johnson Shareholders Demand CEO Pays Out
A Johnson & Johnson CEO paid more than any other pharmaceutical company CEO may be forced to pay back a large amount of that compensation in a recent shareholder lawsuit, according to news reports. The CEO in question has been paid more than $150 million since 2006. Shareholders argue that this is “lavish and excessive”… read more